348 related articles for article (PubMed ID: 25948306)
1. [Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].
Naito T; Kawakami J
Yakugaku Zasshi; 2015; 135(5):709-15. PubMed ID: 25948306
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of oxycodone: a narrative literature review.
Umukoro NN; Aruldhas BW; Rossos R; Pawale D; Renschler JS; Sadhasivam S
Pharmacogenomics; 2021 Apr; 22(5):275-290. PubMed ID: 33728947
[TBL] [Abstract][Full Text] [Related]
3. Fentanyl tolerance in the treatment of cancer pain: a case of successful opioid switching from fentanyl to oxycodone at a reduced equivalent dose.
Sutou I; Nakatani T; Hashimoto T; Saito Y
J Pain Palliat Care Pharmacother; 2015 Jun; 29(2):161-5. PubMed ID: 26095488
[TBL] [Abstract][Full Text] [Related]
4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system.
Takashina Y; Naito T; Mino Y; Yagi T; Ohnishi K; Kawakami J
Drug Metab Pharmacokinet; 2012; 27(4):414-21. PubMed ID: 22277678
[TBL] [Abstract][Full Text] [Related]
6. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
Ruano G; Kost JA
Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
[TBL] [Abstract][Full Text] [Related]
7. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
8. [Feasibility to treat pediatric cancer pain with analgesics for adults and their efficacy].
Zhen ZJ; Sun XF; Xia Y; Ling JY; Zheng L; Luo WB; Lin H
Ai Zheng; 2007 Aug; 26(8):866-9. PubMed ID: 17697549
[TBL] [Abstract][Full Text] [Related]
9. [Difference in tolerance to anti-hyperalgesic effect and its molecular mechanisms between chronic treatment with morphine, fentanyl and oxycodone in a chronic pain-like state].
Satoshi I; Narita M; Ozeki A; Nakamura A; Hashimoto S; Narita M; Kuzumaki N; Uezono Y; Suzuki T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Nov; 28(5-6):169-76. PubMed ID: 19108502
[TBL] [Abstract][Full Text] [Related]
10. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V
J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504
[TBL] [Abstract][Full Text] [Related]
11. Therapy switching in patients receiving long-acting opioids.
Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
[TBL] [Abstract][Full Text] [Related]
12. Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer.
Matsumura C; Yamada M; Fujihara S; Chisaki Y; Takahashi K; Yano Y
Am J Hosp Palliat Care; 2016 Mar; 33(2):109-14. PubMed ID: 25324418
[TBL] [Abstract][Full Text] [Related]
13. [Opioid combination of transdermal fentanyl and oral oxycodone for pain in a patient with giant-cell tumor of the sacrum].
Yoshitake A; Yamamoto T; Susaki S; Abe E
Masui; 2014 Feb; 63(2):199-202. PubMed ID: 24601119
[TBL] [Abstract][Full Text] [Related]
14. Influence of serum albumin levels during opioid rotation from morphine or oxycodone to fentanyl for cancer pain.
Hayashi T; Ikehata S; Matsuzaki H; Yasuda K; Makihara T; Futamura A; Arakawa Y; Kuki R; Fukuura K; Takahashi H; Mori N; Higashiguchi T; Yamadaa S
Biol Pharm Bull; 2014; 37(12):1860-5. PubMed ID: 25590058
[TBL] [Abstract][Full Text] [Related]
15. Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests.
Zhu GD; Whitley P; LaRue L; Adkins B; Dawson E; Huskey A; Capparelli EV; Del Tredici AL
Pharmacogenomics J; 2022 Feb; 22(1):25-32. PubMed ID: 34480108
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
[TBL] [Abstract][Full Text] [Related]
17. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
18. The Current Practice of Opioid for Cancer Dyspnea: The Result From the Nationwide Survey of Japanese Palliative Care Physicians.
Yamaguchi T; Matsunuma R; Suzuki K; Matsuda Y; Mori M; Watanabe H
J Pain Symptom Manage; 2019 Oct; 58(4):672-677.e2. PubMed ID: 31201876
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics-guided analgesics in major abdominal surgery: Further benefits within an enhanced recovery protocol.
Senagore AJ; Champagne BJ; Dosokey E; Brady J; Steele SR; Reynolds HL; Stein SL; Delaney CP
Am J Surg; 2017 Mar; 213(3):467-472. PubMed ID: 27955884
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer.
Bell GC; Donovan KA; McLeod HL
Cancer Control; 2015 Oct; 22(4):426-32. PubMed ID: 26678969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
